Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.

@article{Sominanda2007InterferonBP,
  title={Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.},
  author={Ajith Sominanda and U Rot and Matti Suoniemi and Florian Deisenhammer and Jan Hillert and Anna Fogdell-Hahn},
  journal={Multiple sclerosis},
  year={2007},
  volume={13 2},
  pages={
          208-14
        }
}
Development of neutralizing antibodies (NAbs) reduces the clinical efficacy of interferon beta (IFNbeta) treatment in multiple sclerosis (MS) patients. The aim of this study was to evaluate NAb seroprevalence (frequency of patients with NAbs) and immunogenicity (titer levels) of IFNbeta preparations in a clinical setting. We analysed 1115 consecutive MS patients, treated with one of the three available IFNbeta preparations, for an average of 40 months (1-120 months), for the presence of NAbs… CONTINUE READING
BETA

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS, ESTIMATED 48% COVERAGE

63 Citations

0510'09'12'15'18
Citations per Year
Semantic Scholar estimates that this publication has 63 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…